ICER

News

ICER says US new drug launch prices have risen sharply

ICER says the prices of new drug launches in the US rose 51% in three years, adding up to $1.5bn in first-year costs to US health systems.

News

ICER says GLP-1s 'still have serious affordability issues'

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

Digital

FDA decision casts doubts over future of psychedelic treatme...

Psychedelic therapies have emerged as a promising frontier in mental health treatment, sparking interest from researchers and investors alike.

News

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstru

News

Blood smear from a person with myelodysplastic syndrome

ICER says Geron's just-approved Rytelo is too pricey

Geron's first-in-class cancer drug Rytelo, recently approved by the FDA for myelodysplastic syndromes (MDS), is priced three to four times higher than it should be, according to the Institu

ICER says US new drug launch prices have risen sharply

ICER says GLP-1s 'still have serious affordability issues'

ICER identifies new crop of 'unsupported' drug price rises

FDA decision casts doubts over future of psychedelic treatme...

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

ICER says Geron's just-approved Rytelo is too pricey

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ICER

Editor's Picks